Aphase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Don M. Benson, Craig C. Hofmeister, Swaminathan Padmanabhan, Attaya Suvannasankha, Sundar Jagannath, Rafat Abonour, Courtney Bakan, Pascale Andre, Yvonne Efebera, Jérôme Tiollier, Michael A. Caligiuri, Sherif S. Farag

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Natural killer (NK) cells elicit cytotoxicity against multiple myeloma (MM); however, MM cells express HLA class I molecules as ligands to NK cell inhibitory killer immunoglobulin-like receptors (KIRs) as a means of immunoevasion. KIR-ligand mismatch may improve outcomes in allogeneic transplantation for MM. Extrapolating on this concept, we conducted a phase 1 trial of IPH2101, an anti-KIR antibody, in patients with relapsed/refractory MM. IPH2101 was administered intravenously every 28 days in 7 dose-escalated cohorts (0.0003-3 mg/kg) for up to 4 cycles. Pharmacokinetic, pharmacodynamic, and correlative immunologic studies were completed. A total of 32 patients were enrolled. The biologic endpoint of full KIR2D occupancy across the dosing cycle was achieved without dose-limiting toxicity or maximally tolerated dose. One severe adverse event was noted. Pharmacokinetic and pharmacodynamic findings approximated preclinical predictions, and IPH2101 enhanced ex vivo patient-derived NK cell cytotoxicity against MM. No objective responses were seen. No evidence of autoimmunity was observed. These findings suggest that IPH2101 is safe and tolerable at doses that achieve full inhibitory KIR saturation, and this approach warrants further development in MM. This trial was registered at www.clinicaltrials.gov as #NCT00552396.

Original languageEnglish (US)
Pages (from-to)4324-4333
Number of pages10
JournalBlood
Volume120
Issue number22
DOIs
StatePublished - Nov 22 2012

Fingerprint

KIR Receptors
Multiple Myeloma
Refractory materials
Pharmacodynamics
Pharmacokinetics
Antibodies
Cytotoxicity
Natural Killer Cells
Ligands
Toxicity
Maximum Tolerated Dose
Homologous Transplantation
Autoimmunity
Molecules
IPH 2101

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Aphase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. / Benson, Don M.; Hofmeister, Craig C.; Padmanabhan, Swaminathan; Suvannasankha, Attaya; Jagannath, Sundar; Abonour, Rafat; Bakan, Courtney; Andre, Pascale; Efebera, Yvonne; Tiollier, Jérôme; Caligiuri, Michael A.; Farag, Sherif S.

In: Blood, Vol. 120, No. 22, 22.11.2012, p. 4324-4333.

Research output: Contribution to journalArticle

Benson, DM, Hofmeister, CC, Padmanabhan, S, Suvannasankha, A, Jagannath, S, Abonour, R, Bakan, C, Andre, P, Efebera, Y, Tiollier, J, Caligiuri, MA & Farag, SS 2012, 'Aphase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma', Blood, vol. 120, no. 22, pp. 4324-4333. https://doi.org/10.1182/blood-2012-06-438028
Benson, Don M. ; Hofmeister, Craig C. ; Padmanabhan, Swaminathan ; Suvannasankha, Attaya ; Jagannath, Sundar ; Abonour, Rafat ; Bakan, Courtney ; Andre, Pascale ; Efebera, Yvonne ; Tiollier, Jérôme ; Caligiuri, Michael A. ; Farag, Sherif S. / Aphase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. In: Blood. 2012 ; Vol. 120, No. 22. pp. 4324-4333.
@article{f3da9762fab1418b8fc1ad03fa935e8c,
title = "Aphase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma",
abstract = "Natural killer (NK) cells elicit cytotoxicity against multiple myeloma (MM); however, MM cells express HLA class I molecules as ligands to NK cell inhibitory killer immunoglobulin-like receptors (KIRs) as a means of immunoevasion. KIR-ligand mismatch may improve outcomes in allogeneic transplantation for MM. Extrapolating on this concept, we conducted a phase 1 trial of IPH2101, an anti-KIR antibody, in patients with relapsed/refractory MM. IPH2101 was administered intravenously every 28 days in 7 dose-escalated cohorts (0.0003-3 mg/kg) for up to 4 cycles. Pharmacokinetic, pharmacodynamic, and correlative immunologic studies were completed. A total of 32 patients were enrolled. The biologic endpoint of full KIR2D occupancy across the dosing cycle was achieved without dose-limiting toxicity or maximally tolerated dose. One severe adverse event was noted. Pharmacokinetic and pharmacodynamic findings approximated preclinical predictions, and IPH2101 enhanced ex vivo patient-derived NK cell cytotoxicity against MM. No objective responses were seen. No evidence of autoimmunity was observed. These findings suggest that IPH2101 is safe and tolerable at doses that achieve full inhibitory KIR saturation, and this approach warrants further development in MM. This trial was registered at www.clinicaltrials.gov as #NCT00552396.",
author = "Benson, {Don M.} and Hofmeister, {Craig C.} and Swaminathan Padmanabhan and Attaya Suvannasankha and Sundar Jagannath and Rafat Abonour and Courtney Bakan and Pascale Andre and Yvonne Efebera and J{\'e}r{\^o}me Tiollier and Caligiuri, {Michael A.} and Farag, {Sherif S.}",
year = "2012",
month = "11",
day = "22",
doi = "10.1182/blood-2012-06-438028",
language = "English (US)",
volume = "120",
pages = "4324--4333",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "22",

}

TY - JOUR

T1 - Aphase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

AU - Benson, Don M.

AU - Hofmeister, Craig C.

AU - Padmanabhan, Swaminathan

AU - Suvannasankha, Attaya

AU - Jagannath, Sundar

AU - Abonour, Rafat

AU - Bakan, Courtney

AU - Andre, Pascale

AU - Efebera, Yvonne

AU - Tiollier, Jérôme

AU - Caligiuri, Michael A.

AU - Farag, Sherif S.

PY - 2012/11/22

Y1 - 2012/11/22

N2 - Natural killer (NK) cells elicit cytotoxicity against multiple myeloma (MM); however, MM cells express HLA class I molecules as ligands to NK cell inhibitory killer immunoglobulin-like receptors (KIRs) as a means of immunoevasion. KIR-ligand mismatch may improve outcomes in allogeneic transplantation for MM. Extrapolating on this concept, we conducted a phase 1 trial of IPH2101, an anti-KIR antibody, in patients with relapsed/refractory MM. IPH2101 was administered intravenously every 28 days in 7 dose-escalated cohorts (0.0003-3 mg/kg) for up to 4 cycles. Pharmacokinetic, pharmacodynamic, and correlative immunologic studies were completed. A total of 32 patients were enrolled. The biologic endpoint of full KIR2D occupancy across the dosing cycle was achieved without dose-limiting toxicity or maximally tolerated dose. One severe adverse event was noted. Pharmacokinetic and pharmacodynamic findings approximated preclinical predictions, and IPH2101 enhanced ex vivo patient-derived NK cell cytotoxicity against MM. No objective responses were seen. No evidence of autoimmunity was observed. These findings suggest that IPH2101 is safe and tolerable at doses that achieve full inhibitory KIR saturation, and this approach warrants further development in MM. This trial was registered at www.clinicaltrials.gov as #NCT00552396.

AB - Natural killer (NK) cells elicit cytotoxicity against multiple myeloma (MM); however, MM cells express HLA class I molecules as ligands to NK cell inhibitory killer immunoglobulin-like receptors (KIRs) as a means of immunoevasion. KIR-ligand mismatch may improve outcomes in allogeneic transplantation for MM. Extrapolating on this concept, we conducted a phase 1 trial of IPH2101, an anti-KIR antibody, in patients with relapsed/refractory MM. IPH2101 was administered intravenously every 28 days in 7 dose-escalated cohorts (0.0003-3 mg/kg) for up to 4 cycles. Pharmacokinetic, pharmacodynamic, and correlative immunologic studies were completed. A total of 32 patients were enrolled. The biologic endpoint of full KIR2D occupancy across the dosing cycle was achieved without dose-limiting toxicity or maximally tolerated dose. One severe adverse event was noted. Pharmacokinetic and pharmacodynamic findings approximated preclinical predictions, and IPH2101 enhanced ex vivo patient-derived NK cell cytotoxicity against MM. No objective responses were seen. No evidence of autoimmunity was observed. These findings suggest that IPH2101 is safe and tolerable at doses that achieve full inhibitory KIR saturation, and this approach warrants further development in MM. This trial was registered at www.clinicaltrials.gov as #NCT00552396.

UR - http://www.scopus.com/inward/record.url?scp=84869819029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869819029&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-06-438028

DO - 10.1182/blood-2012-06-438028

M3 - Article

C2 - 23033266

AN - SCOPUS:84869819029

VL - 120

SP - 4324

EP - 4333

JO - Blood

JF - Blood

SN - 0006-4971

IS - 22

ER -